News & Articles

Our new expert webinar series aims to help you get the most from your microbiology research

The company is providing well-characterized and standardized human primary cells with matching specialty cell culture media

The pre-coated Matrigel matrix-3D plates aim to streamline workflows and deliver a more consistent and convenient solution for high-throughput environments

Roche will access SpeeDx existing tests and technology to expand diagnostic products for the management of antibiotic resistance in STIs

These four viral infections have similar patient presentations, making accurate detection and differentiation critical during next flu season

The RECOVERY trial has shown that the cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19

Lonza has collaborated with CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to advance complete 3D cell culture workflows

The test detects antibodies made by the immune system in response to infection by the novel coronavirus in as little as 10 minutes

Companies team-up to promote the use of protein footprinting technologies, products, and contract research services in biopharmaceutical research and development

Flow cytometry expert Kamala Tyagarajan discusses common challenges, offers simple solutions, and shares top tips for experimental success

Find out how scientists are subjecting bacteria to rapid oscillatory osmotic shocks to study the biomechanical basis of cell growth and division

Join us on Wednesday, July 1, to learn about the Lumit™ immunoassay technology and how it can simplify your workflow and yield results faster

Don’t miss this on-demand webinar exploring how RNAscope technology can be used to detect viral infection and pathogenesis

It's comprehensive SARS-COV-2 offerings span RT-PCR, high throughput RNA extraction, automation, ELISA and lateral flow based serology testing.

30 stories from customers, partners and employees celebrate the past and look ahead to joint success in the future

Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London

The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford

Increase the effectiveness of human vaccines against infectious diseases such as COVID-19

Novel platform initially focussed on high-resolution industrial scale processing of therapeutic mRNA